Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.01), $0.10 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $38.5 million versus the consensus estimate of $38.05 million.

Cash, cash equivalents and marketable securities (Cash) were $142.6 million as of September 30, 2016, representing an increase to Cash of $6.6 million in the third quarter of 2016.

"This quarter marks a significant milestone for Vanda, having secured long-term exclusivity for Fanapt and demonstrated our ability to grow our commercial assets and expand our pipeline of products," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.